A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)- amphetamine, p-methoxy amphetamine and harmaline
- 1 October 1980
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 29 (20), 2781-2789
- https://doi.org/10.1016/0006-2952(80)90012-x
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivoJournal of Pharmacy and Pharmacology, 1980
- Inhibition of mouse brain monoamine oxidase by (+)-amphetamine in vivoJournal of Pharmacy and Pharmacology, 1978
- Some pharmacological and biochemical properties of γ-morpholino-butyrophenone (NSD 2023), a new monoamine oxidase inhibitorBiochemical Pharmacology, 1968
- The sub-mitochondrial localization of monoamine oxidase in rat liver and brainBiochimica et Biophysica Acta (BBA) - Biomembranes, 1967
- Selective brain monoamine oxidase inhibition resulting from an interaction between reversible and irreversible inhibitorsInternational Journal of Neuropharmacology, 1965
- A radioisotopic assay for monoamine oxidase determinations in human plasmaBiochemical Pharmacology, 1964
- An analysis of the interaction of reversible and irreversible monoamine oxidase inhibitorsBiochemical Pharmacology, 1964
- INHIBITION OF MONOAMINE OXIDASE BY 2‐METHYL‐3‐PIPERIDINOPYRAZINEAnnals of the New York Academy of Sciences, 1963
- The interaction between reversible and irreversible monoamine oxidase inhibitorsBiochemical Pharmacology, 1960
- Antagonism between harmaline and long-acting monoamine oxidase inhibitors concerning the effect on 5-hydroxytryptamine and norepinephrine metabolism in the brainCellular and Molecular Life Sciences, 1959